# Geneoscopy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneoscopy

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.geneoscopy.com/
- Total disclosed funding: $112M
- Latest round: Series C (Jan 8, 2025)
- Investors on record: 12

## About

Geneoscopy, Inc. is a US-based company specializing in noninvasive diagnostic tests that focus on gastrointestinal health, particularly colorectal cancer screening and management of inflammatory bowel diseases.Founded in 2015 and headquartered in St. Louis, US, Geneoscopy, Inc. develops innovative diagnostic solutions for gastrointestinal health. The company is led by CEO Andrew Barnell, who has a history of entrepreneurship in the health sector. Geneoscopy has successfully raised USD 105 mn in its latest Series C funding round on January 8, 2025, bringing its total amount raised to USD 105 mn and its current valuation to USD 396.63 mn. The funding was supported by several investors including Granger Management and LabCorp Ventures.Geneoscopy specializes in innovative, noninvasive diagnostic tests primarily focused on gastrointestinal health. Their flagship product leverages stool-derived eukaryotic RNA (seRNA) technology to develop molecular-based screening tests for colorectal cancer, aimed at improving the prevention, early detection, and monitoring of this prevalent disease. By utilizing advanced molecular technologies, Geneoscopy addresses significant barriers associated with traditional screening methods, such as colonoscopies, which often deter over 40% of eligible patients from getting screened. The company also focuses on diagnostics for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, enhancing the overall management of gastrointestinal disorders. The primary markets for Geneoscopy's products encompass the United States, where the demand for efficient and effective gastrointestinal diagnostics is substantial.Geneoscopy's revenue is generated through the direct sale of its advanced diagnostic testing services, predominantly to healthcare providers and institutions focusing on gastrointestinal health. These services are structured as a direct-to-consumer model, allowing patients to access testing through their healthcare providers without the need for invasive procedures. The company has established partnerships with various healthcare entities, which facilitates the utilization of their molecular-based tests in clinical settings. Geneoscopy’s pricing strategy is centered around their proprietary seRNA technology, with costs related to their colorectal cancer screening tests structured to be competitive within the diagnostics market. Through these revenue channels, Geneoscopy aims to transform the landscape of gastrointestinal health management while addressing critical health equity issues.Looking ahead, Geneoscopy plans to utilize the USD 105 mn raised in its Series C funding round to advance its colorectal cancer screening test and expand its pipeline for diagnosing inflammatory bowel disease. The company is also strategizing on entering new markets, with specific targets set for expansion in North America and Europe, aiming for a rollout by the end of 2025. These initiatives are geared towards enhancing its product offerings and increasing accessibility to their innovative diagnostic solutions.

## Funding rounds

- Series C, Jan 8, 2025, $105M — LabCorp Ventures, Petrichor, Morningside, NT Investments, Tri Locum Partners, Lightchain Capital, Mercy Health, Granger Management
- Series B, Nov 16, 2021 — BioGenerator, Cultivation Capital, Innovatus Capital Partners, LabCorp Ventures, Morningside, NT Investments, Lightchain Capital
- Series A, Oct 2, 2019, $6.9M — Cultivation Capital, Lightchain Capital, NT Investments
- Seed, Oct 1, 2016 — Dorm Room Fund

## Investors

- Dorm Room Fund (https://capitalatlas.ai/funds/dorm-room-fund) — Seed
- Cultivation Capital (https://capitalatlas.ai/funds/cultivation-capital) — Series A, Series B
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series A, Series B, Series C
- NT Investments — Series A, Series B, Series C
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series B
- Innovatus Capital Partners (https://capitalatlas.ai/funds/innovatus-capital-partners) — Series B
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series B, Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B, Series C
- Petrichor (https://capitalatlas.ai/funds/petrichor) — Series C
- Tri Locum Partners — Series C
- Mercy Health — Series C
- Granger Management (https://capitalatlas.ai/funds/granger-management) — Series C